Anebulo Pharmaceuticals Launches Self-Tender Offer to Go Private

An announcement from Anebulo Pharmaceuticals ( (ANEB) ) is now available.

On December 22, 2025, Anebulo Pharmaceuticals announced that its board had abandoned a previously proposed large reverse stock split and related special shareholder meeting in favor of launching a voluntary self-tender offer as part of its plan to go private. The company intends to commence a cash tender offer to buy up to 300,000 shares of its common stock at $3.50 per share, for a total of up to $1.05 million, a move aimed at keeping its shareholder count below 300, the threshold needed to complete its going-private transaction. The board concluded that the reverse split had become too costly after certain investors distributed holdings across multiple small accounts to maximize fractional share payouts, significantly increasing the projected expense of that strategy. By shifting to the self-tender approach, Anebulo is seeking a more economically efficient path to delisting and deregistration while retaining the option to revisit a reverse split or other structural transaction in the future if conditions change.

The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Spark’s Take on ANEB Stock

According to Spark, TipRanks’ AI Analyst, ANEB is a Underperform.

Anebulo Pharmaceuticals is struggling financially, with no revenue generation and consistent losses. The technical indicators reflect a bearish trend, with the stock trading below key moving averages. Valuation metrics are weak due to negative earnings. While the balance sheet is strong with no debt, the heavy reliance on financing activities poses a risk. Investors should be cautious and consider the company’s ability to achieve profitability and secure future funding.

To see Spark’s full report on ANEB stock, click here.

More about Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., based in Austin, Texas, is a clinical-stage pharmaceutical company focused on developing novel treatments for cannabis-induced toxicity. Its lead drug candidate, selonabant, a competitive human CB1 receptor antagonist, has completed a Phase 2 trial in adults with acute cannabinoid intoxication and is now being prioritized in an intravenous formulation for potential use in pediatric patients, with a Phase 1 single-ascending-dose study of IV selonabant initiated in September 2025.

Average Trading Volume: 21,617

Technical Sentiment Signal: Sell

Current Market Cap: $89.15M

For a thorough assessment of ANEB stock, go to TipRanks’ Stock Analysis page.